Pfizer have come up with their final bid which has been swiftly rejected by the AstraZeneca board as being inadequate. So they have chosen the Red pill and the shares are in the red - down over 10% today as a result.
Guess shareholders will be able to see how AstraZeneca does now as an independent company? However, maybe it is not such a bad thing as I was surprised to read at the weekend in Money week that despite spending $240 billion on three acquisitions in the last 15 years Pfizer's market capitalization today is only $185 billion. So perhaps they are right to be sceptical about the approach although at £55 it was certainly looking expensive if not fully valued in the boards opinion.